SCHEMBL808840

SCHEMBL808840

CCCC(CCC)(C(=O)N[C@@H](c1cccc2ccccc12)C(C)(C)O)C(=O)N[C@@H](c1cccc2ccccc12)C(C)(C)O

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.39
METAP1 P53582 2/20 0.39
SSTR4 P31391 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CNR2 P34972 2/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
EPHX2 P34913 2/20 0.37
GPR139 Q6DWJ6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL809083 0.90 LMNA (0.40) METAP2METAP1SSTR4ALDH1A1LMNA
SCHEMBL808793 0.90 ALDH1A1 (0.40) METAP2METAP1ALDH1A1LMNAGAA
SCHEMBL808783 0.89 ALDH1A1 (0.40) METAP2METAP1SSTR4ALDH1A1LMNA
SCHEMBL808871 0.87 CNR2 (0.38) METAP2METAP1SSTR4ALDH1A1CNR2
SCHEMBL808622 0.87 ALDH1A1 (0.39) METAP2METAP1SSTR4ALDH1A1LMNA
SCHEMBL808670 0.86 METAP2 (0.40) METAP2METAP1SSTR4CNR2LMNA
SCHEMBL809267 0.86 CNR2 (0.40) METAP2METAP1SSTR4CNR2LMNA
SCHEMBL808627 0.86 LMNA (0.42) METAP2METAP1SSTR4ALDH1A1LMNA
SCHEMBL808808 0.85 KMT2A (0.41) METAP2METAP1CNR2LMNAGAA
SCHEMBL808634 0.85 SSTR4 (0.38) METAP2METAP1SSTR4ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1593674-B1 OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-07-20 EP disclosed
US-7683215-B2 Optically active bisoxazoline compounds, process for production of the same and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-23 US disclosed
US-7671213-B2 Optically active bisoxazoline compounds, process for production of the same and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-02 US disclosed
US-20080076931-A1 OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF ITAGAKI MAKOTO 2008-03-27 US disclosed
US-20080076941-A1 OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF ITAGAKI MAKOTO 2008-03-27 US disclosed
US-7288674-B2 Optically active bisoxazoline compounds, process for production of the same and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-10-30 US disclosed
US-20060149077-A1 Optically active bisoxazoline compounds, process for production of the same and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-07-06 US disclosed
EP-1593674-A1 OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060149077-A1 Optically active bisoxazoline compounds, process for production of the same and use thereof ACSL3, ADSL, SQLE METAP2 4249/4885METAP1 3986/4885SSTR4 2560/4885
US-20080076941-A1 OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF ACSL3, ADSL, SQLE METAP2 4249/4885METAP1 3986/4885SSTR4 2560/4885
US-20080076931-A1 OPTICALLY ACTIVE BISOXAZOLINE COMPOUNDS, PROCESS FOR PRODUCTION OF THE SAME AND USE THEREOF ACSL3, ADSL, SQLE METAP2 4249/4885METAP1 3986/4885SSTR4 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.